Business
Hemostemix Announces Its Webinar for Florida Vascular Surgeons: Autologous Stem Cell Therapy for CLTI
Calgary, Alberta--(Newsfile Corp. - October 28, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMT...
About this update from Hemostemix Inc
[{"type":"text","content":"Hemostemix Announces Its Webinar for Florida Vascular Surgeons: Autologous Stem Cell Therapy for CLTICalgary, Alberta--(Newsfile Corp. - October 28, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option individuals suffering from pain related to angina, peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, is pleased to announce a one-hour educational webinar for Florida vascular surgeons and healthcare professionals. The session will introduce ACP-01, Hemostemix's innovative autologous stem cell therapy designed for patients who suffer in pain with chronic limb-threatening ischemia (CLTI) who have no revascularization options.Amputation rates among no-option CLTI patients remain unacceptably high: 12,059 in 2023, for example, based on statewide inpatient hospitalizations where a lower-extremity amputation occurred. ACP-01 offers a safe, minimally invasive alternative that utilizes a patient's own blood-derived cells to stimulate angiogenesis, restore microcirculation, and promote natural tissue healing.Scheduled for Wednesday, October 29, 2025, at 12:00 PM ET, this Florida-focused webinar will equip attendees with the clinical knowledge and operational tools to offer ACP-01 therapy in their own practices or to refer patients under Florida's compassionate use framework, Statute s. 381.985.\"We're delighted to build on our boots on the ground campaign, to bring this targeted education to Florida's vascular surgeons,\" said Thomas Smeenk, President & CEO of Hemostemix. \"In this session, physicians will walk away with everything they need to start treatment of eligible patients,\" Smeenk said.Webinar Agenda: \"Everything You Need to Treat CLTI with ACP-01 in Florida\"This interactive session will cover key clinical and operational aspects, offering immediate, actionable insights for Florida-based practitioners:Introduction to ACP-01: Explore the science behind this blood-derived, autologous cell therapy that promotes angiogenesis without immunosuppression or complex surgical procedures.Patient Qualification: Identify ideal candidates-Rutherford class 4-5 patients with non-healing ulcers...